Pfizer Announces FDA Approval for PADCEV Plus Keytruda Combination Therapy for Muscle-Invasive Bladder Cancer
On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma announced the U.S. Food and Drug Administration approved a new treatment combination of PADCEV plus Keytruda or Keytruda QLEX for adult patients with muscle-invasive bladder cancer. This marks the first platinum-free regimen approved for this condition regardless of cisplatin eligibility, based on results from the Phase 3 EV-304 trial.
Tickers: $PFE